Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures
- PMID: 8987090
- DOI: 10.1023/a:1016053729362
Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures
Abstract
Purpose: Previous studies by other investigators have shown an enhancement of mitomycin C (MMC) activity at acidic extracellular pH (pHe) in monolayer cultures of human cells. The goal of the present study was to determine if the efficacy of intravesical MMC therapy in patients treated for superficial bladder cancer can be enhanced by using acidified dosing solutions. We evaluated (a) the effect of pHe on MMC activity in patient bladder tumors in vitro, and (b) the pH dependency of MMC activity in 2-dimensional monolayer and 3-dimensional multilayer cultures of human bladder RT4 tumor cells.
Methods: Patient bladder tumors were maintained as 3-dimensional histocultures. RT4 cells were harvested and maintained as monolayer cultures or as 3-dimensional cell pellets on a collagen gel matrix. The cell pellets were 300-450 cell layers and 4,000-5,000 microns in diameter. Tumors or cells were incubated for 2 hr with MMC-containing media at pHe of 5, 6, and 7.4. The drug effect was measured by the inhibition of DNA precursor (thymidine) incorporation. The stability of MMC as a function of pHe was determined. About 24% of MMC was degraded following 2 hr exposure at pHe 5 and < or = 2% at pHe 6 and 7.4.
Results: The drug concentrations required to inhibit thymidine incorporation by 50% (IC50) were corrected for the degraded MMC at acidic pHe. The results showed no pH-dependent MMC activity in human patient bladder tumors nor in RT4 multilayer cultures; the IC50 values were about 10 micrograms/ml at all three pHe. In contrast, the monolayer RT4 cultures showed a pH-dependent MMC cytotoxicity; the IC50 were 0.1, 0.8 and 1.2 micrograms/ ml at pHe 5, 6 and 7.4, respectively (p < 0.05). Pre-incubation of multilayered RT4 cultures in acidic pH medium for 8 hr enhanced the MMC activity; the IC50 was reduced by about 5 fold at pHe about 3 fold at pHe 6. Similar pH-dependent MMC activity was found when multilayers were pre-treated for 1 hr with 0.5 microgram/ml nigericin, a proton ionophore known to cause the intracellular pH (pHi) to equilibrate with pHe.
Conclusions: These data suggest that the difference in the pH dependency of MMC activity in the monolayer and multilayer systems was due to the different experimental conditions. The time lag for pHi to equilibrate with pHe in the multilayer systems and the instability of MMC at low pHe imply that the efficacy of intravesical MMC therapy is unlikely to be enhanced by using acidic dosing solution.
Similar articles
-
Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.BJU Int. 2011 Apr;107(7):1154-61. doi: 10.1111/j.1464-410X.2010.09543.x. Epub 2010 Aug 24. BJU Int. 2011. PMID: 20735383
-
Pharmacodynamics of mitomycin C in cultured human bladder tumors.Cancer Res. 1991 Aug 1;51(15):3849-56. Cancer Res. 1991. PMID: 1906778
-
Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology.J Urol. 1994 Nov;152(5 Pt 1):1632-6. doi: 10.1016/s0022-5347(17)32493-x. J Urol. 1994. PMID: 7933219
-
[Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports].Acta Urol Belg. 1996 Mar;64(1):47-53. Acta Urol Belg. 1996. PMID: 8659335 Review. French.
-
Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.Expert Opin Drug Deliv. 2008 Jan;5(1):137-45. doi: 10.1517/17425247.5.1.137. Expert Opin Drug Deliv. 2008. PMID: 18095933 Review.
Cited by
-
Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study.Drug Des Devel Ther. 2013;7:1-6. doi: 10.2147/DDDT.S39541. Epub 2012 Dec 28. Drug Des Devel Ther. 2013. PMID: 23300343 Free PMC article. Clinical Trial.
-
Intravesical treatments of bladder cancer: review.Pharm Res. 2008 Jul;25(7):1500-10. doi: 10.1007/s11095-008-9566-7. Epub 2008 Mar 28. Pharm Res. 2008. PMID: 18369709 Free PMC article. Review.
-
Current animal models of bladder cancer: Awareness of translatability (Review).Exp Ther Med. 2014 Sep;8(3):691-699. doi: 10.3892/etm.2014.1837. Epub 2014 Jul 11. Exp Ther Med. 2014. PMID: 25120584 Free PMC article.
-
Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures.Pharm Res. 1998 Nov;15(11):1760-6. doi: 10.1023/a:1011921031564. Pharm Res. 1998. PMID: 9834000
-
A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.Br J Cancer. 2001 Oct 19;85(8):1137-46. doi: 10.1054/bjoc.2001.2056. Br J Cancer. 2001. PMID: 11710826 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical